RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here's Why [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
Beam Therapeutics Inc. (NASDAQ: BEAM ) is one of the top gene therapy stocks to buy according to hedge funds . On February 25, RBC Capital adjusted the price target on Beam Therapeutics Inc. (NASDAQ:BEAM) to $26 from $22 and maintained a Sector Perform rating on the shares. The rating update came after the company reported its fiscal Q4 financial results, with the firm telling investors that Beam Therapeutics Inc. (NASDAQ:BEAM) is continually targeting BLA submission this year on sickle cell disease, and announced a non-dilutive debt deal with Sixth Street to support potential commercialization. Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? Beam Therapeutics Inc. (NASDAQ:BEAM) reported its fiscal Q4 and full-year 2025 results on February 24 and also announced the expansion of its liver-targeted genetic disease franchise with a new program, BEAM-304, for the treatment of phenylketonuria (PKU). PKU has a considerable unmet need and affects around 20,000 indiv
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics (BEAM) had its price target raised by Royal Bank Of Canada from $22.00 to $26.00. They now have a "sector perform" rating on the stock.MarketBeat
- Beam Therapeutics (BEAM) had its price target raised by Wedbush from $57.00 to $65.00. They now have an "outperform" rating on the stock.MarketBeat
- Beam Therapeutics Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)GlobeNewswire
BEAM
Earnings
- 2/24/26 - Beat
BEAM
Sec Filings
- 2/26/26 - Form 4
- 2/24/26 - Form 144
- 2/24/26 - Form S-8
- BEAM's page on the SEC website